These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 25691681)

  • 21. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Lioulios G; Stangou M; Sarafidis PA; Tsouchnikas I; Minasidis I; Vainas A; Faitatzidou D; Sampani E; Papagianni A
    Blood Purif; 2020; 49(4):440-447. PubMed ID: 32050202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    Kidney Int Rep; 2018 Jan; 3(1):185-192. PubMed ID: 29340330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
    Kalantar-Zadeh K; Ficociello LH; Zhou M; Anger MS
    BMC Nephrol; 2024 Jun; 25(1):197. PubMed ID: 38886636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
    Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Pai AB; Jang SM; Wegrzyn N
    Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
    Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
    Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
    Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
    Otsuki T; Utsunomiya K; Moriuchi M; Horikoshi S; Okamura M; Suzuki H; Okamura M; Maruyama N; Shibahara N; Abe M
    Nephron; 2018; 140(3):161-168. PubMed ID: 29991053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
    Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
    J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L
    Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
    Isaka Y; Fujii H; Tsujimoto Y; Teramukai S; Hamano T
    Clin Exp Nephrol; 2018 Aug; 22(4):967-972. PubMed ID: 29536389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study.
    Ferreira A; Pinto B; Navarro D; Aniceto J; Neves PL; Ponce P
    J Bras Nefrol; 2019; 41(2):224-230. PubMed ID: 30742699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
    Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
    Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
    Greenbaum LA; Jeck N; Klaus G; Fila M; Stoica C; Fathallah-Shaykh S; Paredes A; Wickman L; Nelson R; Swinford RD; Abitbol CL; Balgradean M; Jankauskiene A; Perrin A; Enoiu M; Ahn SY
    Pediatr Nephrol; 2021 May; 36(5):1233-1244. PubMed ID: 33106892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.